Latest Incyte Corporation Stories
INDIANAPOLIS and WILMINGTON, Del., Dec.
RESEARCH TRIANGLE PARK, N.C., May 19 /PRNewswire/ -- ArtusLabs, Inc. (www.artuslabs.com), the leader in scientifically-aware data management systems, today announced a collaborative license agreement with Incyte Corporation to address two prevalent industry problems.
Incyte Corporation (Nasdaq:INCY) announced today the presentation of clinical results from a 28-day Phase IIa trial of INCB18424, its orally available janus kinase (JAK) inhibitor, in patients with rheumatoid arthritis (RA).
Incyte Corporation (Nasdaq:INCY) reported positive results from two 28-day Phase IIa clinical trials of topical INCB18424, a selective janus-associated kinase (JAK) inhibitor, in patients with mild to moderate psoriasis.
Incyte Corporation (Nasdaq:INCY) today announced its second quarter 2008 financial results and reported continued progress in several lead clinical programs.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.